Immune Checkpoint Inhibitors in Resectable and Locoregionally Advanced HNSCC: Past Lessons, Present Evidence, and Future Directions.

Jeerapradit K, Keam B, Ngamphaiboon N

Open source

DOI
10.1093/oncolo/oyag366
Published
2026 Sep 17
Container
The oncologist
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1093/oncolo/oyag366,
  title = {Immune Checkpoint Inhibitors in Resectable and Locoregionally Advanced HNSCC: Past Lessons, Present Evidence, and Future Directions.},
  author = {Jeerapradit K and Keam B and Ngamphaiboon N},
  year = {2026},
  journal = {The oncologist},
  doi = {10.1093/oncolo/oyag366},
  url = {https://doi.org/10.1093/oncolo/oyag366}
}

RIS

TY  - JOUR
TI  - Immune Checkpoint Inhibitors in Resectable and Locoregionally Advanced HNSCC: Past Lessons, Present Evidence, and Future Directions.
AU  - Jeerapradit K
AU  - Keam B
AU  - Ngamphaiboon N
PY  - 2026
JO  - The oncologist
DO  - 10.1093/oncolo/oyag366
UR  - https://doi.org/10.1093/oncolo/oyag366
ER  - 

APA

K, J., B, K., & N, N. (2026). Immune Checkpoint Inhibitors in Resectable and Locoregionally Advanced HNSCC: Past Lessons, Present Evidence, and Future Directions.. The oncologist. https://doi.org/10.1093/oncolo/oyag366

Source records